目的 了解2011-2016年成都地区21家医院抗肿瘤靶向药物的使用情况及变化趋势，为临床合理用药提供参考。方法 对成都地区21家医院2011-2016年抗肿瘤靶向药物的销售金额、用药频度（DDDs）、日均费用（DDC）进行统计分析。结果 2011-2016年成都地区21家医院抗肿瘤靶向药物的使用金额波动较大，2013年使用金额最大，2015年降至最低；曲妥珠单抗、吉非替尼和索拉菲尼的使用金额大幅降低，伊马替尼的使用金额呈不断增加趋势。曲妥珠单抗、吉非替尼和厄洛替尼的DDDs大幅降低，伊马替尼的DDDs急剧增加。抗肿瘤靶向药物的DDC整体波动较小，美妥昔单抗的DDC最高，其次为西妥昔单抗。结论 成都地区21家医院抗肿瘤靶向药物的使用合理，符合安全、有效、经济、方便原则。

Objective To investigate the utilization and trend of anti-tumor targeted drugs in 21 hospitals in Chengdu area from 2011 to 2016, and to provide a reference for clinical drug use. Methods Consumption sums, defined daily dose (DDDs), and average daily cost (DDC) of anti-tumor targeted drugs in 21 hospitals in Chengdu area from 2011 to 2016 were comprehensively analyzed. Results Consumption sums of anti-tumor targeted drugs had larger fluctuation in 21 hospitals in Chengdu area from 2011 to 2016. Consumption sums in 2013 were the largest, while those in 2015 decreased to the lowest. Consumption sums of trastuzumab, gefitinib, and sorafenib were sharply decreased, while consumption sum of imatinib had an increasing trend. DDDs of trastuzumab, gefitinib, and erlotinib were sharply decreased, while DDDs of imatinib were sharply increased. DDC of anti-tumor targeted drugs had less fluctuation on the whole. DDC of metuximab was the biggest, and then was cetuximab. Conclusion The utilization of anti-tumor targeted drugs in 21 hospitals in Chengdu area is reasonable, according with the principle of safety, effectiveness, economy and convenience.